Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05742594 · ClinicalTrials.gov registry record · Phase 1
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT05742594 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 64 participants.
The verdict
NCT05742594, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the bioequivalence of four different lazertinib oral tablet formulations in healthy adult participants under fasted condition.
Interventions
- DRUG Lazertinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2023-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05742594
The ClinicalTrials.gov registry entry for NCT05742594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lazertinib is the first listed.
NCT05742594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05742594 about?
NCT05742594 is a clinical study titled "A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants". The purpose of this study is to assess the bioequivalence of four different lazertinib oral tablet formulations in healthy adult participants under fasted condition.
What is the current status of trial NCT05742594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2023-01-03. Estimated completion is 2023-04-03.
What interventions are being tested in trial NCT05742594?
The interventions under investigation include: Lazertinib (DRUG).
Who is sponsoring clinical trial NCT05742594?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.